Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab170481-100μg | 100μg | In stock | $79.90 | |
| Ab170481-1mg | 1mg | In stock | $378.90 | |
| Ab170481-5mg | 5mg | In stock | $1,323.90 | |
| Ab170481-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,992.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Alemtuzumab (anti-CD52) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to CD52, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | Alemtuzumab; Cambridge pathology 1 antigen antibody; CAMPATH 1 antibody; CAMPATH 1 antigen antibody; CAMPATH-1 antigen antibody; CD 52 antibody; CD52 antibody; CD52 antigen antibody; CD52 molecule antibody; CD52_HUMAN antibody; CDw52 antibody; CDW52 antig |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | CD52 |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | Antibody of CD52 |
| Product Description | Alemtuzumab (anti-CD52) is a recombinant monoclonal antibody to CD52, a glycoprotein expressed on the surface of most lymphoid, and to a lesser extent, myeloid cell types. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| Light Chain Type | kappa |
| SDS-PAGE | 27.2 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 194.0 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 216503-57-0 |
Alemtuzumab (anti-CD52) (Ab170481) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD52 with Alemtuzumab (anti-CD52) (Ab170481) conjugated with biotin (right panel) compared with Human IgG (Ab170213) conjugated with biotin - Isotype Control (left panel) and detected with SA-PE (rp156250).
Alemtuzumab (anti-CD52) (Ab170481) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD52 (red) with Alemtuzumab (anti-CD52) (Ab170481) conjugated with biotin and detected with SA-PE (rp156250). Blue - Isotype control, human IgG (Ab170213) conjugated with biotin. Black - Unlabelled control, cells without incubation with primary antibody.
Alemtuzumab (anti-CD52) (Ab170481) - SEC
The purity of Alemtuzumab (anti-CD52) (Ab170481) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| IMGT/mAb-DB | 11 |
|---|---|
| Wikipedia | Alemtuzumab |
| PEP | alemtuzumab |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0303663 | Certificate of Analysis | Mar 25, 2024 | Ab170481 |
| ZJ24F0303662 | Certificate of Analysis | Mar 25, 2024 | Ab170481 |
| ZJ24F0303661 | Certificate of Analysis | Mar 25, 2024 | Ab170481 |
| 1. Crowe JS, Hall VS, Smith MA, Cooper HJ, Tite JP. (1992) Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material.. Clin Exp Immunol, 87 (1): (105-10). [PMID:1339322] |
| 2. Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA et al.. (2016) Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.. Neurology, 87 (19): (1985-1992). [PMID:27733571] |
